Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.340
+0.170 (7.83%)
Nov 20, 2025, 4:00 PM EST - Market closed
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,403,250
Market Cap
348.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PALI News
- 23 days ago - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - GlobeNewsWire
- 4 weeks ago - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
- 5 weeks ago - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewsWire
- 6 weeks ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewsWire
- 2 months ago - Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data - GlobeNewsWire